Health Catalyst, Inc. (NASDAQ:HCAT) Receives $11.71 Average Price Target from Analysts

Health Catalyst, Inc. (NASDAQ:HCAT) has been assigned a consensus rating of “Moderate Buy” from the twelve brokerages that are covering the firm, MarketBeat.com reports. Three research analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $11.79.

A number of equities analysts have issued reports on the stock. Piper Sandler restated an “overweight” rating and set a $12.00 target price (up previously from $11.00) on shares of Health Catalyst in a research report on Tuesday, November 26th. Citigroup lifted their price objective on Health Catalyst from $9.00 to $10.50 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. JPMorgan Chase & Co. increased their target price on Health Catalyst from $10.00 to $13.00 and gave the company an “overweight” rating in a report on Wednesday, September 4th. Cantor Fitzgerald reissued an “overweight” rating and set a $16.00 price target on shares of Health Catalyst in a research report on Friday, October 4th. Finally, Evercore ISI upped their price objective on Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a research report on Tuesday, October 8th.

Insider Activity

In other Health Catalyst news, COO Daniel Lesueur sold 5,209 shares of the firm’s stock in a transaction dated Thursday, October 3rd. The stock was sold at an average price of $7.68, for a total value of $40,005.12. Following the sale, the chief operating officer now directly owns 134,899 shares of the company’s stock, valued at approximately $1,036,024.32. This trade represents a 3.72 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Kevin Lee Freeman sold 7,500 shares of Health Catalyst stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total value of $54,150.00. Following the completion of the sale, the insider now owns 255,881 shares of the company’s stock, valued at $1,847,460.82. This trade represents a 2.85 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 34,068 shares of company stock valued at $257,555 over the last quarter. Company insiders own 2.50% of the company’s stock.

Hedge Funds Weigh In On Health Catalyst

Large investors have recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD increased its holdings in shares of Health Catalyst by 6.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 49,746 shares of the company’s stock worth $375,000 after buying an additional 2,831 shares during the last quarter. Kennedy Capital Management LLC acquired a new stake in Health Catalyst during the first quarter worth about $8,780,000. Virtus Investment Advisers Inc. purchased a new position in shares of Health Catalyst in the 1st quarter worth about $115,000. SG Americas Securities LLC purchased a new position in shares of Health Catalyst in the 2nd quarter worth about $187,000. Finally, Nepsis Inc. lifted its stake in shares of Health Catalyst by 8.3% in the 2nd quarter. Nepsis Inc. now owns 1,253,080 shares of the company’s stock valued at $8,007,000 after purchasing an additional 95,686 shares in the last quarter. Hedge funds and other institutional investors own 85.00% of the company’s stock.

Health Catalyst Stock Performance

NASDAQ HCAT opened at $8.83 on Monday. The business has a 50 day moving average price of $8.12 and a 200 day moving average price of $7.33. The company has a market capitalization of $537.29 million, a P/E ratio of -6.54 and a beta of 1.32. Health Catalyst has a 1-year low of $5.42 and a 1-year high of $11.41. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41.

Health Catalyst (NASDAQ:HCAT) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. The firm had revenue of $76.40 million for the quarter, compared to analyst estimates of $76.27 million. During the same period last year, the firm earned ($0.22) EPS. The company’s quarterly revenue was up 3.5% compared to the same quarter last year. Sell-side analysts expect that Health Catalyst will post -0.33 EPS for the current fiscal year.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.